View Cart (0 items)

Pharmaceutical

PACK EXPO 2014 expected to set attendance records

PMMI, the Association for Packaging and Processing Technologies, predicts 2014 will set some new records for PACK EXPO International and the debut of Pharma EXPO.
Read More

Three Nigerian pharmaceutical firms get WHO certification

Three pharmaceutical manufacturers in Nigeria have been certified by the World Health Organization (WHO) to produce drugs in accordance with its Good Manufacturing Practice (GMP).
Read More

Auxilium Pharmaceuticals agrees to acquisition deal with Endo

Specialty biopharmaceutical company Auxilium Pharmaceuticals, Inc. is to be acquired by Endo International plc for $2.6 billion, including the repayment and assumption of debt.
Read More

Teva to end cancer, women's health research

Generic drugmaker Teva Pharmaceutical Industries Ltd. has decided to stop research and development in a number of areas, including oncology and women's health, as part of efforts to cut costs.
Read More

Antibiotics, heavy metals in the environment contribute to resistance

Very low concentrations of antibiotics and heavy metals in the environment contribute to antibiotic resistance, a new Swedish study has demonstrated.
Read More

Consort agrees to $372 million acquisition of Aesica

U.K.-based healthcare company Consort Medical plc announced on Tuesday an agreement to acquire Aesica Pharmaceuticals.
Read More

Pfizer acquires InnoPharma

Pharmaceutical giant Pfizer Inc. has completed its acquisition of InnoPharma Inc., the company announced on Thursday.
Read More

PCI acquires clinical trail services company Biotec

Pharmaceutical packaging services provider PCI has expanded its presence in the European Union with the acquisition of Biotec Services International.
Read More

New heart failure drug could cut deaths by 20%

Swiss pharmaceuticals group Novartis is planning to launch a new drug that has the potential to cut cardiovascular death and admissions to hospital by 20%.
Read More

New facility to research personalized cellular cancer therapies

A new facility to develop personalized cellular cancer therapies will be built by the University of Pennsylvania, funded in part with a $20 million investment from Novartis.
Read More